New method may allow personalized clinical trial for cancer therapies
A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy and may offer a way to further refine personalized cancer treatments.
The approach, developed by investigators at Vanderbilt-Ingram Cancer Center, shows that erlotinib a targeted therapy that acts on a growth factor receptor mutated in some lung, brain and other cancers doesn't simply kill tumor cells as was previously assumed. The drug also causes some tumor cells to go into a non-dividing (quiescent) state or to slow down their rate of division. This variability in cell response to the drug may be involved in cancer recurrence and drug resistance, the authors suggest.
The new tool, reported Aug. 12 in Nature Methods, may offer ways to improve personalized cancer therapy by predicting tumor response and testing combinations of targeted therapies in an individual patient's tumor.
In the personalized approach to cancer treatment, a patient's tumor is analyzed for a set of mutations to which there are matching drugs that act on those mutations.
This approach has worked rather well for many cancers that carry specific mutations, said senior author Vito Quaranta, M.D., professor of Cancer Biology.
"The genetics is well understood, the clinical effect is understood and the chemistry behind the therapy is understood. But there is a missing piece," said Quaranta. "Believe it or not, what is actually not understood is how cells respond to these drugs, what is actually happening."
The prevailing view has been that targeted therapies kill all the cells harboring a particular mutation.
But even if the tumor is composed entirely of genetically identical cells which is unlikely a drug will not affect all cells the same way, Quaranta explained.
"Some of these cells may die, some may just stop dividing and sit there (called quiescence), and some may keep dividing, but more slowly."
However, no current tests can provide an accurate, detailed picture of cell behavior needed to understand tumor response to drugs.
So, the investigators, led by first author Darren Tyson, Ph.D., research assistant professor of Cancer Biology, combined powerful automated, time-lapse microscopy with analytical tools and software they developed.
Using these techniques, they could capture the behavior of lung cancer cells every six to 10 minutes for up to 10 days.
As they expected, the targeted therapy erlotinib killed some cells, while others became quiescent. They observed that the drug even affected genetically identical cells (cells that arose from the same parental cell) differently.
"These cells are clearly genetically identical, as identical as they can possibly be because one cell just divided into two, but you get completely different responses: one dies and the other one doesn't," said Tyson. "This suggests that there are other things besides genetics that have to be taken into account."
What those other factors are remains unclear, but the investigators are conducting follow- up experiments to determine what might underlie this differential response.
"And presumably, it is those (quiescent) cells that ultimately result in tumor recurrence," said Tyson.
Quaranta and colleagues hope to take the technology into small clinical trials to test whether it can predict a patient's response to therapy.
"We think that we might be able to forecast what the response is going to be," Quaranta said. "We can take samples from the tumor, subject them to this assay, and since we're looking at response over time, we will have a rate of response."
This could tell oncologists how long a patient's tumor will respond to a given therapy before it recurs. Such information could also help determine which patients will require more aggressive treatment and Quaranta believes the assay will be able to test combinations of drugs on a patient's tumor cells to find the right combination to induce a response.
"We're hoping that this assay or some implementation of this assay will eventually work like a personalized clinical trial," Quaranta said.
Journal reference: Nature Methods
Provided by Vanderbilt University Medical Center
- Researchers find possible 'master switch' in deadly brain cancer 7 minutes ago | not rated yet | 0
- Research offers promising new approach to treatment of lung cancer 17 hours ago | not rated yet | 0
- Study details genes that control whether tumors adapt or die when faced with p53 activating drugs 17 hours ago | not rated yet | 0
- Poliovirus vaccine trial shows early promise for recurrent glioblastoma May 21, 2013 | not rated yet | 0
- Team finds mechanism linking key inflammatory marker to cancer May 20, 2013 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
3 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.
Cancer 13 hours ago | not rated yet | 0
National Lung Screening Trial (NLST) investigators also conclude that the 20 percent reduction in lung cancer mortality with low-dose computed tomography (LDCT) versus chest X-ray (CXR) screening previously reported in the ...
Cancer 14 hours ago | not rated yet | 0
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage ...
Cancer 17 hours ago | not rated yet | 0 |
When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die – the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even i ...
Cancer 17 hours ago | not rated yet | 0 |
Study leader, Professor John Mathews from the University of Melbourne said this small increase in cancer risk must be weighed against the undoubted benefits from CT scans in diagnosing and monitoring disease.
Cancer 22 hours ago | not rated yet | 0
US teen births have dropped to a record low, but the country still has one of the highest rates among developed nations, the US Centers for Disease Control and Prevention said Thursday.
54 minutes ago | not rated yet | 0
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
18 hours ago | 4.9 / 5 (9) | 1 |
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
18 hours ago | 4.7 / 5 (3) | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
15 hours ago | 5 / 5 (2) | 2 |
Existing research shows that bicyclists who wear helmets have an 88 percent lower risk of brain injury, but researchers at Boston Children's Hospital found that simply having bicycle helmet laws in place showed a 20 percent ...
7 hours ago | not rated yet | 0
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
15 hours ago | 4.3 / 5 (3) | 0 |